8-K: BioCryst Pharmaceuticals Announces Price Increase for ORLADEYO in the U.S.

BioCryst Pharmaceuticals is increasing the wholesale acquisition cost of ORLADEYO in the United States effective January 8, 2025.

Summary

• BioCryst Pharmaceuticals has announced an increase in the wholesale acquisition cost (WAC) for its drug ORLADEYO in the United States.
• The price will increase from $42,366.03 to $44,484.33 per 28-day pack, for both 150mg and 110mg capsules.
• This price change is effective as of January 8, 2025.

Sentiment

Score: 5

Explanation: The document is neutral in tone, simply stating a price increase. While a price increase is generally positive for the company's revenue, it could have negative implications for patients and payers, hence a neutral score.

Negatives

• The price increase of ORLADEYO may negatively impact patients and payers.
• The increased cost could affect the affordability and accessibility of the medication.

Risks

• The price increase could lead to reduced sales volume if patients switch to alternative treatments or if payers restrict access.
• There is a risk of negative public perception due to the price increase.

Industry Context

Price increases for pharmaceutical products are common, but they can be controversial and may face scrutiny from regulators and the public. This price increase could be a strategic move to increase revenue, but it also carries risks related to market access and public perception.

Comparison to Industry Standards

• Comparing this price increase to other specialty drugs in the rare disease space, it is important to consider the overall cost of treatment and the availability of alternatives.
• Other companies such as Takeda and CSL Behring also have treatments for hereditary angioedema (HAE), and their pricing strategies and market share will be relevant to assess the impact of this price increase.
• The price increase of approximately 5% is within the range of typical annual price adjustments for branded pharmaceuticals, but the absolute dollar increase is significant given the high cost of the drug.

Stakeholder Impact

• Shareholders may view the price increase positively as it could lead to increased revenue.
• Patients and payers may be negatively impacted by the increased cost of ORLADEYO.
• Employees may be indirectly affected by the company's financial performance.

Key Dates

Keywords

ORLADEYO, BioCryst Pharmaceuticals, price increase, wholesale acquisition cost, WAC, berotralstat, pharmaceuticals, drug pricing